RU2189971C1 - Highly labeled with tritium - Google Patents

Highly labeled with tritium Download PDF

Info

Publication number
RU2189971C1
RU2189971C1 RU2001113520A RU2001113520A RU2189971C1 RU 2189971 C1 RU2189971 C1 RU 2189971C1 RU 2001113520 A RU2001113520 A RU 2001113520A RU 2001113520 A RU2001113520 A RU 2001113520A RU 2189971 C1 RU2189971 C1 RU 2189971C1
Authority
RU
Russia
Prior art keywords
tritium
labeled
highly labeled
methanol
organic chemistry
Prior art date
Application number
RU2001113520A
Other languages
Russian (ru)
Inventor
В.П. Шевченко
Н.Ф. Мясоедов
И.Ю. Нагаев
Original Assignee
Институт молекулярной генетики РАН
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Институт молекулярной генетики РАН filed Critical Институт молекулярной генетики РАН
Priority to RU2001113520A priority Critical patent/RU2189971C1/en
Application granted granted Critical
Publication of RU2189971C1 publication Critical patent/RU2189971C1/en

Links

Landscapes

  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

FIELD: organic chemistry, hormones, radiolabeled compounds. SUBSTANCE: Invention relates to synthesis of a novel highly labeled analog of physiologically active compound O-(4-hydroxy-3,5-diiodophenyl)-3',5'-diiodo-L-tyrosine ("thyroxine") of the formula (I)

Description

Изобретение относится к области органической химии и может найти применение в аналитической химии, биоорганической химии, биохимии и прикладной медицине. The invention relates to the field of organic chemistry and can find application in analytical chemistry, bioorganic chemistry, biochemistry and applied medicine.

При изучении физиологически активных соединений необходимы их меченые аналоги. When studying physiologically active compounds, their labeled analogues are necessary.

Известен O-(4-гидрокси-3,5-дииодофенил)- 3',5'-дииодо-L-тирозин формулы I:

Figure 00000003

Данное соединение, получившее наименование "тироксин", является гормональным препаратом (E. Syniewski. //Ann./Thorac.Surg. 1993, v.56, S2-S8;
D.A. Fisher.//Clin.Chem.l996. v.42, p.135-139).Known O- (4-hydroxy-3,5-diiodophenyl) - 3 ', 5'-diiodo-L-tyrosine of the formula I:
Figure 00000003

This compound, called "thyroxine", is a hormonal drug (E. Syniewski. //Ann./Thorac.Surg. 1993, v.56, S2-S8;
DA Fisher.//Clin.Chem.l996. v. 42, p. 135-139).

Однако его меченный тритием аналог не описан. However, its tritium-labeled counterpart is not described.

Техническим результатом, достигаемым настоящим изобретением, является расширение ассортимента меченых аналогов физиологически активных соединений. The technical result achieved by the present invention is to expand the range of labeled analogues of physiologically active compounds.

Достигается указанный технический результат получением высокомеченного тритием O-(4-гидрокси-3,5-дииодофенил)- 3',5'-дииодо-L-тирозина формулы I. This technical result is achieved by obtaining highly labeled with tritium O- (4-hydroxy-3,5-diiodophenyl) - 3 ', 5'-diiodo-L-tyrosine of the formula I.

Ниже приведен пример реализации изобретения. The following is an example implementation of the invention.

Пример. Example.

В реакционную ампулу помещали 20 мг тироксина, нанесенного на 200 мг катализатора Линдлара. Затем ампулу вакуумировали до давления 0,1 Па, заполняли газообразным тритием до давления 333 гПа и выдерживали при температуре 180oС 10 мин, после чего удаляли избыточный тритий вакуумированием. В ампулу вносили 5 мл метанола, катализатор отфильтровывали, фильтрат упаривали и удаляли лабильный тритий трехкратным упариванием с метанолом. Остаток растворяли в 0,5 мл метанола и меченый препарат выделяли из реакционной смеси методом ВЭЖХ. Выход искомого меченого препарата достигал 20-25%, молярная радиоактивность - 6,5 Kи/ммоль.20 mg of thyroxine supported on 200 mg of Lindlar catalyst were placed in a reaction vial. Then the ampoule was evacuated to a pressure of 0.1 Pa, filled with gaseous tritium to a pressure of 333 hPa and kept at a temperature of 180 ° C. for 10 minutes, after which excess tritium was removed by vacuum. 5 ml of methanol was added to the ampoule, the catalyst was filtered off, the filtrate was evaporated and labile tritium was removed by evaporation three times with methanol. The residue was dissolved in 0.5 ml of methanol and the labeled preparation was isolated from the reaction mixture by HPLC. The yield of the desired labeled preparation reached 20-25%, the molar radioactivity was 6.5 Ki / mmol.

Анализ и очистку меченого препарата проводили высокоэффективной жидкостной (ВЭЖХ) хроматографией (Separon 7 мкм, C18•150 мм, скорость (v) элюента 0,5 мл/мин, в системе 90% метанол - 50 мМ фосфатный буфер (рН 2,8), время удерживания 2,21 мин; в системе 70% метанол - 10 мМ фосфорная кислота, время удерживания 19,21 мин, в системе 75% метанол - 10 мМ фосфорная кислота, время удерживания 24,12 мин, на колонке Silasorb 15 мкм, C18, 10х250 мм, v - 1,0 мл/мин, - 2,0 мл/мин; в системе 85% метанол - 0,2% уксусная кислота - 0,015% трифторуксусная кислота, время удерживания 12,60 мин, на колонке Kromasil 100 С18, 4,6х150 мм; в системе 80% метанол - 10 мМ фосфорная кислота, v - 1,0 мл/мин, - 1,0 мл/мин, время удерживания 2,48 мин).The labeled preparation was analyzed and purified by high performance liquid chromatography (HPLC) (Separon 7 μm, C 18 • 150 mm, eluent speed (v) 0.5 ml / min, in a 90% methanol system — 50 mM phosphate buffer (pH 2.8 ), retention time 2.21 min; in the 70% methanol system - 10 mM phosphoric acid, retention time 19.21 min, in the 75% methanol system - 10 mM phosphoric acid, retention time 24.12 min, on a Silasorb column 15 μm , C 18 , 10x250 mm, v - 1.0 ml / min, - 2.0 ml / min; in the system 85% methanol - 0.2% acetic acid - 0.015% trifluoroacetic acid, retention time 12.60 min, column Kromasil 100 C18, 4,6h150 m; in the system 80% methanol - 10 mM phosphoric acid, v - 1,0 ml / min - 1.0 ml / min, retention time 2.48 min).

Таким образом получено новое высокомеченное тритием физиологически активное соединение. Thus, a new physiologically active compound highly labeled with tritium was obtained.

Claims (1)

Высокомеченный тритием О-(4-гидрокси-3,5-дийодофенил)-3', 5'-дийодо-L-тирозин формулы 1
Figure 00000004
Highly labeled tritium O- (4-hydroxy-3,5-diiodophenyl) -3 ', 5'-diiodo-L-tyrosine of formula 1
Figure 00000004
RU2001113520A 2001-05-22 2001-05-22 Highly labeled with tritium RU2189971C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2001113520A RU2189971C1 (en) 2001-05-22 2001-05-22 Highly labeled with tritium

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2001113520A RU2189971C1 (en) 2001-05-22 2001-05-22 Highly labeled with tritium

Publications (1)

Publication Number Publication Date
RU2189971C1 true RU2189971C1 (en) 2002-09-27

Family

ID=20249729

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2001113520A RU2189971C1 (en) 2001-05-22 2001-05-22 Highly labeled with tritium

Country Status (1)

Country Link
RU (1) RU2189971C1 (en)

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Е. Syniewski; Ann. Thorac. Surg.; 1993, v. 56, р.52-58 D.A. Fisher; Clin. Chem.; 1996, v. 42, р.135-139. *

Similar Documents

Publication Publication Date Title
JP5604423B2 (en) Method for preparing Caspofungin and its intermediate
JP4468806B2 (en) Ferrocene compounds and uses thereof
RU2189971C1 (en) Highly labeled with tritium
US10036743B2 (en) Cationic tags for attomole level detection of analytes by mass spectrometry
JP2019055921A (en) Method of producing stereoisomer
RU2323224C1 (en) Tritium uniformly labeled 3h-amphotericin b
Ramalingam et al. An improved synthesis of S-adenosylhomocysteine and related compounds
RU2318806C1 (en) Tritium uniformly labeled [3h]-trans-3,7-dimethyl-9-(2,6,6-trimethyl-3-oxo-1-cyclohexene-1-yl)-2,4,6,8-nonatetraenic acid
RU2326889C1 (en) α-HEDERIN UNIFORMLY MARKED WITH TRITIUM
RU2268256C1 (en) Tritium high-labeled [3h]-(e)-n-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-noneneamide
RU2233285C1 (en) Highly tritium labeled [3h]-rapamycin
RU2368613C1 (en) Uniformly tritium-labeled 4,4-difluoro-n-{(1s)-3-[3-(3-isopropyl-5-methyl-4h-1,2,4-triazol-4-yl)-8-azabicyclo[3,2,1]oct-8-yl]-1-phenylpropyl}cyclohexane carbodiimide
RU2206562C1 (en) Highly tritium-labeled 7-(4'-dimethylaminophenyl)-7-oxo-2,4-heptadiene hydroxamic acid
RU2265025C1 (en) Highly labeled with tritium [3h]-2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid
RU2351606C1 (en) Uniformly tritiated triterpene glycosides of holothurians cucumaria
RU2291142C1 (en) 2-AMINO-4-(β-HYDROXYETHYLAMINO)ANISOLE UNIFORMLY LABELED WITH TRITIUM
RU2229469C1 (en) Butyrylcholine chloride highly labeled with tritium
RU2197457C1 (en) High-tritium-labeled n-methyl-n-2-propinylbenzylamine
RU2309929C2 (en) Chlorohexidine highly labeled with tritium
RU2291147C2 (en) [3h]-fluvastatin highly labeled with tritium
RU2248965C1 (en) Tritium highly labeled [3h]-(s)-alpha-cyano-3-phenoxybenzyl-(1r)-(2',2'-dibromovinyl)-2,2-dimethyl cyclopropane carboxylate
RU2155175C2 (en) Tritium highly marked-(2-ano-2-methoxyiminoacetyl)-3- ethylurea
RU2190591C1 (en) 2-methyl-3-phythyl-1,4-naphthoquinone highly labeled with tritium
RU2513852C1 (en) UNIFORMLY TRITIUM-LABELLED PYRO-Glu-His-Pro-NH2
RU2499786C1 (en) UNIFORMLY LABELLED (3aS, 5S, 6R, 7aR, 7bS, 9aS, 10R, 12aS, 12bS)-10-[(2S, 3R, 4R, 5S)-3,4-DIHYDROXY-5,6-DIMETHYL-2-HEPTANYL]-5,6-DIHYDROXY-7a,9a-DIMETHYLHEXADECANE HYDRO-3H-BENZO [c]INDENO [5,4-e]OXEPIN-3-ONE TRIMER

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20110523